Journals / Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi / 2009 / Cilt: 10 - Sayı: 3

Prolonged high levels of ca 19-9 after cholecystectomy: A case report

Kolesistektomi sonrası uzamış ca 19-9 yüksekliği: Olgu sunumu

Pages
43–45
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It should be considered that prolonged high levels of CA 19-9 might occur after cholecystectomy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Carbohydrate antigen 19-9 (CA 19-9), is a glycosphingolipid known as one of the serum tumor markers.
📊
Key Findings & Data:Although CA 19-9 is a tumor marker which used in pancreatic, biliary, hepatocellular and gastrointestinal malignancies, high levels of CA 19-9 have also been reported in pancreatitis and benign biliary tract diseases as cholangitis, cholecystitis, choledocholithiasis.
💡
Conclusion & Impact:It should be considered that prolonged high levels of CA 19-9 might occur after cholecystectomy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Carbohydrate antigen 19-9 (CA 19-9), is a glycosphingolipid known as one of the serum tumor markers. Although CA 19-9 is a tumor marker which used in pancreatic, biliary, hepatocellular and gastrointestinal malignancies, high levels of CA 19-9 have also been reported in pancreatitis and benign biliary tract diseases as cholangitis, cholecystitis, choledocholithiasis. In this case report, we present a case with prolonged high levels of CA 19-9 after cholecystectomy. Case was a 41 years-old patient who had laparascopic cholecystectomy operation due to chronic cholecystitis and high levels of CA 19-9. The levels of CA 19-9 increased up to 2169 U/mL and returned to normal levels five months after the operation. It should be considered that prolonged high levels of CA 19-9 might occur after cholecystectomy.

Özet

Karbonhidrat antijeni 19-9 (CA 19-9) gliko spingo lipid yapıda olup serum tümör belirteci olarak bilinir. CA 19-9 pankreatik, bilier, hepatosellüler ve gastrointestinal sistem kanserlerinde kullanılan bir tümör belirleyici olmasına rağmen pankreatit ve kolanjit, kolesistit, koledokolitiazis gibi benign safra kanalı hastalıklarında da yüksek olabilmektedir. Biz bu olgu sunumunda kolesistektomi sonrası uzun süren yükselmiş CA 19-9 seviyesi olan vakayı sunuyoruz. Bu vaka 41 yaşında olup kronik kolesistit nedeniyle laparoskopik kolesistektomi operasyonu yapılan ve yükselmiş CA 19-9 düzeyi saptanan bir hastaydı. Operasyon sonrası CA 19-9 seviyesi 2169 U/mL seviyesine kadar yükselmiş olup, operasyon sonrası 5. ayda normale döndü. Kolesistektomi sonrası uzun süren CA 19-9 seviyesi yüksekliği akılda tutulmalıdır.

🔖

Cite This Article

TURTAY, M. G., CEYLAN, C. (2022). Prolonged high levels of ca 19-9 after cholecystectomy: A case report. Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi, Cilt: 10 - Sayı: 3, 43–45. https://ajindex.com/articles/428978

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5
  2. Ayyıldız MO, Kızılay E, Müftüoğlu E. Tümör markırları ve klinik kullanım alanları. T Klin Tıp Bilimleri 1999;19:114-22
  3. Gülşen MT, Büyükberber M, Kis C, Kadayıfçı A, Koruk M, Savaş MC. Yüksek CA 19-9 seviyeleri ile seyreden bir benign biliyer darlık olgusu. Turkiye Klinikleri J Gastroenterohepatol 2004;15:122-5 4) Şahin M, Cüre E, İşler M, Barut İ. Elevated CA 19-9 levels in patient with cholecystitis. Fırat Tıp Dergisi 2007;12(1):81-83
  4. Sheen-Chen SM, Sun CK, Liu YW, Eng HL, Ko SF, Kuo CH. Extremely elevated CA 19-9 in acute cholangitis. Dig Dis Sci 2007;52:3140-2
  5. Arends JW, Verstynen C, Bosman FT, Hilgers J, Steplewski Z. Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma 1983;2(2):219-29
  6. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, et al. A new strategy for the application of CA 19-9 in the differentiation of pancreatico-biliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999;94:1941-6
  7. Ohshio G, Manabe T, Watanabe Y, Endo K, Kudo H, Suzuki T, et al. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA 19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Am J Gastroenterol 1990;85:1370-6
  8. Buccheri GF, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A, et al. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer 1987;60:42-50
  9. Yiğitbaşı R, Karabıçak İ, Aydoğan F, Ertürk S, Bican O, Aydın O, et al. Benign splenic epithelial cyst accompanied by elevated CA 19-9 level: a case report. Mt Sinai J Med 2006;73(6):871-3
  10. Akdoğan M, Şaşmaz N, Kayhan B, Biyikoğlu I, Dişibeyaz S, Sahin B. Extraordinarily elevated CA 19-9 in benign conditions: a case report and review of the literature. Tumori 2001;87:337-9
  11. Katsonos KH, Kitsanou M, Christodoulou DK, Tsianos EV. High CA 19-9 levels in benign biliary tract diseases report of four cases and review of the literature. Eur J Intern Med 2002;13:132-135
  12. Lin CL, Changchien CS, Chen YS. Mirizzi� syndrome with a high CA 19-9 level mimicking cholangiocarcinoma. Am J Gastroenterol 1997;92:2309-10
  13. Milionis HJ, Elisaf MS, Tsianos EV. P